The series A fundraising is the biggest ever for a European biotech firm, according to the data provider PitchBook.

El Lilly’s blockbuster weight-loss drug Zepbound is now eligible for coverage under Medicare prescription drug plans, when ...

Novo Nordisk, the largest European company by market capitalization, has achieved worse than expected results for its new ...

A new generation of obesity drugs – such as Novo Nordisk A/S’ Wegovy and Eli Lilly and Company’s Zepbound – is changing the perception of obesity as a multifaceted illness that requires ...

Bosses from Fortune 500 Europe companies including Novo Nordisk, Lego, and Carlsberg met with the PM as Trump ups his threats ...

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be ...

The analysts expect launches of medicines including Eli Lilly’s Zepbound and Novo Nordisk ... failure drugs across the U.S., the five main European markets and Japan totaled $13.5 billion ...

Terence Flynn, Biotech Analyst at Morgan Stanley, discusses Eli Lilly's recent stock boost and its designation as Morgan Stanley's top pick for 2025. He highlights the robust growth potential of Eli ...

Moreover, Novo Nordisk is now the most valuable company in Europe -- ahead of luxury fashion ... while its sibling treatment, Zepbound, is geared toward chronic weight management.

The Series A funding round by the start-up, co-founded by executives of Aiolos Bio, the biotech that was sold to GSK last year for $1.4bn, was led by US firm General Atlantic and European life ...